Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein…
History, Community, Culture & Applications
Explore the main themes, entities and connections around Infliximab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
approved disease tnf patients treatment antibody use crohn's monoclonal chimeric psoriasis mouse colitis arthritis european united states human ulcerative medical
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Infliximab | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Infliximab | ATC code | L04AB02 (WHO) | 1.00 | infobox |
| Infliximab | Bioavailability | 92% (IV, if 8% left in the syringe) | 1.00 | infobox |
| Infliximab | Biosimilars | infliximab-abda, infliximab-axxq, infliximab-dyyb, infliximab-qbtx, Avsola, Flixabi, Inflectra, Ixifi, Remsima, Renflexis, Zessly, Zymfentra | 1.00 | infobox |
| Infliximab | CAS Number | 170277-31-3 Y | 1.00 | infobox |
| Infliximab | ChEMBL | ChEMBL1201581 N | 1.00 | infobox |
| Infliximab | ChemSpider | none | 1.00 | infobox |
| Infliximab | CompTox Dashboard (EPA) | DTXSID9040504 | 1.00 | infobox |
| Infliximab | DrugBank | DB00065 Y | 1.00 | infobox |
| Infliximab | Elimination half-life | 9.5 days | 1.00 | infobox |
| Infliximab | Formula | C6428H9912N1694O1987S46 | 1.00 | infobox |
| Infliximab | KEGG | D02598 Y | 1.00 | infobox |
| Infliximab | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Infliximab | Legal status | CA: ℞-only / Schedule D | 1.00 | infobox |
| Infliximab | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Infliximab | Legal status | US: ℞-only | 1.00 | infobox |
| Infliximab | Legal status | EU: Rx-only | 1.00 | infobox |
| Infliximab | License data | US DailyMed: Infliximab | 1.00 | infobox |
| Infliximab | MedlinePlus | a604023 | 1.00 | infobox |
| Infliximab | Metabolism | reticuloendothelial system | 1.00 | infobox |
| Infliximab | Molar mass | 144190.64 g·mol−1 | 1.00 | infobox |
| Infliximab | Pregnancy category | AU: C | 1.00 | infobox |
| Infliximab | Routes of administration | Intravenous, subcutaneous | 1.00 | infobox |
| Infliximab | Source | Chimeric (mouse/human) | 1.00 | infobox |
| Infliximab | Target | Tumor necrosis factors (TNF) | 1.00 | infobox |
| Infliximab | Trade names | Remicade, others | 1.00 | infobox |
| Infliximab | Type | Whole antibody | 1.00 | infobox |
| Infliximab | UNII | B72HH48FLU | 1.00 | infobox |
| Infliximab | is a | chimeric monoclonal antibody biologic | 0.90 | text |
| Infliximab | is a | therapeutic alternative on the World Health Organization's List of Essential Medicines..mw-parser-output .toclimit-2 .toclevel-1 ul | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.